ClinicalTrials.gg
CompletedNCT04180488Updated Aug 20, 2025Results posted

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

A Phase 3 interventional study of Dupilumab SAR231893 and Placebo in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 98 sites in 11 countries. Open to participants aged 6 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
6 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
13th of 58
397 · median 132
Started
2019
with 5 others
Phase 3
21 of 64
1 open now
Registered
26th of 64
by date
Lead sponsor
3 of 64
Sanofi

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2019, is one of 21 in phase 3, and was the 26th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 6 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders)

Secondary Objectives:

This study aimed to demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints This study aimed to demonstrate the efficacy of dupilumab on angioedema This study aimed to demonstrate the efficacy of dupilumab on urticaria control This study aimed to demonstrate improvement in health-related quality of life and overall disease status and severity This study aimed to evaluate the ability of dupilumab in reducing the proportion of participants who require treatment with oral corticosteroids (OCS) This study aimed to evaluate safety outcome measures This study aimed to evaluate immunogenicity of dupilumab

Read the detailed description

The duration of study for each participant included 2-4 weeks of screening period, 24 weeks of treatment period and 12 weeks of post treatment period.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
6 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study A and C: Participant were ≥6 years to 80 years of age at the time of signing the .
  • Study B: Participant were ≥12 years (or the minimum legal age for adolescents in the country of the site) to 80 years of age at the time of signing the informed consent
  • Participants who had a diagnosis of CSU to H1 antihistamines (H1-AH) at the time of randomization defined by
  • Diagnosis of CSU>6 months prior to screening visit
  • Presence of itch and hives for >6 consecutive weeks at any time prior to screening visit despite the use of H1-AH during that time period
  • Used a study defined H1-antihistamine for CSU treatment
  • During the 7 days before randomization:

UAS7≥16 ISS7≥ 8

  • Study A and C: omalizumab naïve, Study B; intolerant or incomplete responder to omalizumab
  • Participants were willing and able to complete a daily symptom e-Diary for the duration of the study

Exclusion criteria

Exclusion Criteria:

Participants were excluded from any of the studies if any of the following criteria apply:

  • Weight was less than 30 kg in adults and adolescents and 15 kg in children aged 6 to\<12years
  • Clearly defined underlying etiology for chronic urticarias other than CSU
  • Presented of skin morbidities other than CSU that may interfere with the assessment of the study outcomes
  • Active atopic dermatitis
  • Severe concomitant illness(es) that, in the investigator's judgment, would have adversely affected the participant's participation in the study
  • Active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis unless documented adequately treated.
  • Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit and during the screening period
  • Known or suspected immunodeficiency
  • Active or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin
  • History of systemic or anaphylaxis to omalizumab or any biologic therapy, including any
  • Participation in prior dupilumab clinical study, or have been treated with commercially available dupilumab.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
397 participants (actual)

Study arms

  • Experimental
    Study A Dupilumab

    Participants who were omalizumab naïve received dupilumab for 24 weeks as follows: * 300 milligrams (mg) SC injection every 2 weeks (q2w) for adults and those adolescents who weighed \>=60 kilograms (kg) at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1, * 200 mg SC injection q2w for adolescents who weighed \<60 kg and children (\>=6 to \<12 years of age) who weighed \>=30 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1 and * 300 mg SC injection every 4 weeks (q4w) for children (\>=6 to \<12 years of age) who weighed \<30 kg and \>=15 kg at screening starting from Week 4 following a loading dose of 600 mg (2×300 mg injections) on Day 1.

    Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine

  • Placebo comparator
    Study A Placebo

    Participants who were omalizumab naïve received placebo matched to dupilumab as subcutaneous (SC) injection including loading dose from Day 1 up to 24 weeks.

    Drug: Placebo · Drug: non sedating H1-antihistamine

  • Experimental
    Study B Dupilumab

    Participants who were intolerant or incomplete responders to omalizumab received dupilumab for 24 weeks as follows: * 300 mg SC injection q2w for adults and those adolescents weighing \>=60 kg at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1 or * 200 mg SC injection q2w for adolescents weighing \<60 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1.

    Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine

  • Placebo comparator
    Study B Placebo

    Participants who were intolerant or incomplete responders to omalizumab received placebo matched to dupilumab as SC injection including loading dose from Day 1 up to 24 weeks.

    Drug: Placebo · Drug: non sedating H1-antihistamine

  • Experimental
    Study C Dupilumab

    Participants who were omalizumab naïve received dupilumab for 24 weeks as follows: * 300 mg SC injection q2w for adults and those adolescents who weighed \>=60 kg at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1, * 200 mg SC injection q2w for adolescents who weighed \<60 kg and children (\>=6 to \<12 years of age) who weighed \>=30 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1 and * 300 mg SC injection q4w for children (\>=6 to \<12 years of age) who weighed \<30 kg and \>=15 kg at screening starting from Week 4 following a loading dose of 600 mg (2×300 mg injections) on Day 1.

    Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine

  • Placebo comparator
    Study C Placebo

    Participants who were omalizumab naïve received placebo matched to dupilumab as SC injection including loading dose from Day 1 up to 24 weeks.

    Drug: Placebo · Drug: non sedating H1-antihistamine

Interventions

  • Pharmaceutical form:Injection solution Route of administration: Subcutaneous

  • DrugPlacebo

    Pharmaceutical form:Injection solution Route of administration: Subcutaneous

  • Drugnon sedating H1-antihistamine

    Pharmaceutical form:Tablet Route of administration: oral administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Itch Severity Score at Week 24

    ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Least squares (LS) mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

    Time frame: Baseline (Day 1) and Week 24

Secondary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score at Week 24

    UAS is a validated composite patient-reported outcome (PRO) measure for assessing chronic spontaneous urticaria (CSU) activity. The once daily UAS is the sum of the daily hives severity score (HSS) and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day 1) and Week 24

  2. Change From Baseline in Weekly Hives Severity Score at Week 24

    Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day 1) and Week 24

  3. Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 24

    The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.

    Time frame: Week 24

  4. Percentage of Participants With Weekly Urticaria Activity Score <=6 at Week 24

    UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria.

    Time frame: Week 24

  5. Percentage of Participants With Weekly Urticaria Activity Score =0 at Week 24

    UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.

    Time frame: Week 24

  6. Change From Baseline in Urticaria Control Test (UCT) at Week 24

    The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

    Time frame: Baseline (Day 1) and Week 24

  7. Change From Baseline in Weekly Itch Severity Score at Week 12

    ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. LS mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

    Time frame: Baseline (Day 1) and Week 12

  8. Change From Baseline in Weekly Urticaria Activity Score at Week 12

    UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day 1) and Week 12

  9. Percentage of Participants With Weekly Urticaria Activity Score <=6 and =0 at Week 12

    UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria and an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.

    Time frame: Week 12

  10. Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 12

    The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.

    Time frame: Week 12

  11. Change From Baseline in Weekly Hives Severity Score at Week 12

    Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day 1) and Week 12

  12. Change From Baseline in Urticaria Control Test at Week 12

    The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

    Time frame: Baseline (Day 1) and Week 12

  13. Change From Baseline in Weekly Itch Severity Score at Weeks 4, 8, 16 and 20

    ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

    Time frame: Baseline (Day 1) and Weeks 4, 8, 16 and 20

  14. Time to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period

    The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. The MID for ISS7 was a change of 5.0 points. Time to first ISS7 MID response (ISS7 \>=5) was defined as time to reduction from baseline of 5 points or more. Kaplan-Meier estimate is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

    Time frame: Baseline (Day 1) up to Week 24

  15. Change From Baseline in Angioedema Activity Score Over 7 Days (AAS7) at Weeks 12 and 24

    The AAS is a diary in which participants document on a daily basis the presence or absence of angioedema during the past 24 hours. If angioedema is present, participants answer 5 additional questions about the time of the day the swelling episode occurred and the severity and impact on daily functioning and appearance this swelling episode has had. Each AAS item is scored between 0 (minimum) and 3 (maximum). The daily AASs range from 0 (no episode) to 15 (severe) points. The AAS7 score is the sum of daily AAS scores reported by a participant at the same time of each day over 7 days, with a range of 0 (no angioedema episodes) to 105 (highest angioedema severity). Higher scores indicate greater angioedema activity. Mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day 1) and Weeks 12 and 24

  16. Percentage of Well-controlled Participants (Urticaria Control Test >=12) at Weeks 12 and 24

    The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; QoL impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. An UCT score of \>=12 (out of maximum 16) indicated a well-controlled urticaria disease status.

    Time frame: Weeks 12 and 24

  17. Change From Baseline in Health-related Quality-of-life (HRQoL) as Measured by Dermatology Life Quality Index (DLQI) in Participants >=16 Years Old at Weeks 12 and 24

    The DLQI is an assessment assessing the impact of skin disease on participants' HRQoL over the previous week and contains 10 questions related to symptoms, leisure activities, work/school or holiday time, personal relationships including intimate, the side effects of treatment, and emotional reactions to having a skin disease. The questions (except question 7) were scored on a 4-point Likert scale: 0 (not at all), 1 (a little), 2 (a lot), 3 (very much). Question 7 about work/studying asked whether work/study had been prevented and then (if "No") to what degree the skin condition has been a problem at work/study; the item was again rated on a 3-point Likert scale: 0 (not at all) to 3 (a lot). Total DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

    Time frame: Baseline (Day 1) and Weeks 12 and 24

  18. Change From Baseline in Health-related Quality-of-life as Measured by Children's Dermatology Life Quality Index (CDLQI) in Participants >=6 to <16 Years Old at Weeks 12 and 24

    The CDLQI is a validated questionnaire designed to measure the impact of skin disease on children's HRQoL. Participants provide responses to 10 questions (symptoms feelings associated with disease, the impact of the disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease). The instrument has a recall period of 7 days. 9 of the 10 questions are scored on a 4-point Likert scale ranging from 0 (not at all/question unanswered) to 3 (very much). Question 7 has an additional possible response (prevented school) which is assigned a score of 3 (0 \[not at all\] to 3 \[definitely\]). The total CDLQI score is the sum of the score of each question ranging 0 (no impact) to 30 (severe impact). The higher the score, the greater the impact is on the child's HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

    Time frame: Baseline (Day 1) and Weeks 12 and 24

  19. Patient Global Impression of Change (PGIC) of Chronic Spontaneous Urticaria at Weeks 12 and 24

    The PGIC is a 1-item questionnaire that asks the participant to provide the overall self-assessment of change in their CSU on a 7-point scale compared to just before participant started taking the study intervention. Response choices are: 0 (very much better), 1 (moderately better), 2 (a little better), 3 (no change), 4 (a little worse), 5 (moderately worse), 6 (very much worse). Higher score indicate worsening.

    Time frame: Weeks 12 and 24

  20. Change From Baseline in Patient Global Impression of Severity (PGIS) of Chronic Spontaneous Urticaria at Weeks 12 and 24

    The PGIS is a 1-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Response choices are: 1 (none), 2 (mild), 3 (moderate), 4 (severe). Higher score indicate more severity. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

    Time frame: Baseline (Day 1) and Weeks 12 and 24

  21. Time to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period

    Participants receiving OCS as rescue medications for CSU were recorded by the Investigator in e-case report form (eCRF) during the 24-week treatment period. Kaplan-Meier estimate for time to first OCS use is presented.

    Time frame: Baseline (Day 1) up to Week 24

  22. Percentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period

    Percentage of participants receiving OCS as rescue medications for CSU were recorded by the Investigator in eCRF during the 24-week treatment period.

    Time frame: Baseline (Day 1) up to Week 24

  23. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

    Time frame: From first dose of study intervention (Day 1) up to end of follow-up, approximately 36 weeks each for Study A, B and C

  24. Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab

    Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.

    Time frame: Up to Week 24

07

Results

Posted Aug 20, 2025

Participant flow

This study comprised of 3 randomized studies of similar design: 2 studies were conducted in participants who were omalizumab naïve (Study A \[55 centers in 9 countries\] and Study C \[50 centers in 9 countries\]) and 1 study was conducted in participants who were omalizumab intolerant or incomplete responders (Study B \[61 centers in 11 countries\]).

Participant flow — Overall Study
MilestoneStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Started687054547774
Completed556347496766
Not completed13775108
Withdrew: Not related to coronavirus disease-2019 (covid-19)211322
Withdrew: Withdrawal by subject845286
Withdrew: Adverse event320000
Withdrew: Poor compliance to protocol001000

Outcome measures

PrimaryChange From Baseline in Weekly Itch Severity Score at Week 24

ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Least squares (LS) mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Itch Severity Score at Week 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Itch Severity Score at Week 24-6.01 ± 0.94-10.24 ± 0.91-4.81 ± 1.08-7.68 ± 1.10-6.10 ± 1.40-8.64 ± 1.41
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · ANCOVA · p = 0.0005 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -4.23 · 95% CI -6.63 to -1.84
  • Study B: Placebo vs Study B: Dupilumab · ANCOVA · p = 0.0449 (Threshold for significance at 2-sided 0.043 level.) · Ls mean difference: -2.87 · 95% CI -5.68 to -0.07
  • Study C: Placebo vs Study C: Dupilumab · ANCOVA · p = 0.0184 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -2.54 · 95% CI -4.65 to -0.43
SecondaryChange From Baseline in Weekly Urticaria Activity Score at Week 24

UAS is a validated composite patient-reported outcome (PRO) measure for assessing chronic spontaneous urticaria (CSU) activity. The once daily UAS is the sum of the daily hives severity score (HSS) and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Urticaria Activity Score at Week 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Urticaria Activity Score at Week 24-12.00 ± 1.81-20.53 ± 1.76-8.54 ± 2.14-14.37 ± 2.16-11.21 ± 2.65-15.86 ± 2.66
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · ANCOVA · p = 0.0003 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -8.53 · 95% CI -13.16 to -3.90
  • Study C: Placebo vs Study C: Dupilumab · ANCOVA · p = 0.0226 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -4.65 · 95% CI -8.65 to -0.65
SecondaryChange From Baseline in Weekly Hives Severity Score at Week 24

Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Hives Severity Score at Week 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Hives Severity Score at Week 24-5.90 ± 0.93-10.28 ± 0.91-3.63 ± 1.11-6.64 ± 1.11-5.11 ± 1.31-7.27 ± 1.32
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · ANCOVA · p = 0.0003 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -4.38 · 95% CI -6.78 to -1.98
  • Study C: Placebo vs Study C: Dupilumab · ANCOVA · p = 0.0316 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -2.17 · 95% CI -4.15 to -0.19
SecondaryPercentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 24

The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 24
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 2442.672.938.959.351.970.3
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0014 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 3.413 · 95% CI 1.596 to 7.299
  • Study C: Placebo vs Study C: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0109 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 2.507 · 95% CI 1.231 to 5.107
SecondaryPercentage of Participants With Weekly Urticaria Activity Score <=6 at Week 24

UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Urticaria Activity Score <=6 at Week 24
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Percentage of Participants With Weekly Urticaria Activity Score <=6 at Week 2423.545.718.524.123.440.5
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0075 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 2.848 · 95% CI 1.301 to 6.234
  • Study C: Placebo vs Study C: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0045 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 3.137 · 95% CI 1.371 to 7.176
SecondaryPercentage of Participants With Weekly Urticaria Activity Score =0 at Week 24

UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Urticaria Activity Score =0 at Week 24
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Percentage of Participants With Weekly Urticaria Activity Score =0 at Week 2413.231.49.313.018.229.7
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0199 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 2.908 · 95% CI 1.173 to 7.209
  • Study C: Placebo vs Study C: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0187 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 2.677 · 95% CI 1.127 to 6.359
SecondaryChange From Baseline in Urticaria Control Test (UCT) at Week 24

The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urticaria Control Test (UCT) at Week 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Urticaria Control Test (UCT) at Week 244.88 ± 0.617.71 ± 0.593.38 ± 0.745.33 ± 0.774.16 ± 0.945.09 ± 0.95
Statistical analysis
  • Study C: Placebo vs Study C: Dupilumab · ANCOVA · p = 0.1940 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: 0.93 · 95% CI -0.48 to 2.34
SecondaryChange From Baseline in Weekly Itch Severity Score at Week 12

ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. LS mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Itch Severity Score at Week 12
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Itch Severity Score at Week 12-6.01 ± 0.85-8.37 ± 0.84-4.52 ± 0.95-7.37 ± 0.97-5.31 ± 1.32-7.15 ± 1.32
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · ANCOVA · p = 0.0377 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -2.37 · 95% CI -4.60 to -0.13
SecondaryChange From Baseline in Weekly Urticaria Activity Score at Week 12

UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Urticaria Activity Score at Week 12
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Urticaria Activity Score at Week 12-11.79 ± 1.64-16.81 ± 1.62-8.22 ± 1.91-13.33 ± 1.94-9.51 ± 2.54-12.87 ± 2.54
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · ANCOVA · p = 0.0223 (Threshold for significance at 2-sided 0.05 level.) · Ls mean difference: -5.02 · 95% CI -9.32 to -0.72
SecondaryPercentage of Participants With Weekly Urticaria Activity Score <=6 and =0 at Week 12

UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria and an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Urticaria Activity Score <=6 and =0 at Week 12
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
UAS7 <=617.634.39.324.116.931.1
UAS7=08.815.71.913.011.717.6
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0215 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 2.645 · 95% CI 1.154 to 6.061
SecondaryPercentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 12

The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 12
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 1252.970.046.364.851.958.1
Statistical analysis
  • Study A: Placebo vs Study A: Dupilumab · Cochran-Mantel-Haenszel · p = 0.0971 (Threshold for significance at 2-sided 0.05 level.) · Odds ratio (or): 1.872 · 95% CI 0.893 to 3.923
SecondaryChange From Baseline in Weekly Hives Severity Score at Week 12

Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Hives Severity Score at Week 12
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Weekly Hives Severity Score at Week 12-5.69 ± 0.83-8.39 ± 0.83-3.71 ± 1.01-5.97 ± 1.02-4.22 ± 1.28-5.75 ± 1.28
SecondaryChange From Baseline in Urticaria Control Test at Week 12

The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urticaria Control Test at Week 12
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Change From Baseline in Urticaria Control Test at Week 124.62 ± 0.576.48 ± 0.573.11 ± 0.655.48 ± 0.673.26 ± 0.884.61 ± 0.89
SecondaryChange From Baseline in Weekly Itch Severity Score at Weeks 4, 8, 16 and 20

ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

Time frame:
Baseline (Day 1) and Weeks 4, 8, 16 and 20
Reported as:
Mean · score on a scale
Change From Baseline in Weekly Itch Severity Score at Weeks 4, 8, 16 and 20
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 4-3.30 ± 6.54-4.96 ± 5.49-4.12 ± 6.28-5.51 ± 5.64-3.78 ± 4.73-5.26 ± 5.16
Week 8-4.98 ± 7.49-6.99 ± 6.78-4.27 ± 5.92-7.25 ± 6.29-4.92 ± 5.67-7.83 ± 6.02
Week 16-5.61 ± 7.45-9.43 ± 6.86-4.52 ± 6.68-8.05 ± 7.43-6.22 ± 5.78-8.24 ± 7.37
Week 20-6.40 ± 7.82-10.04 ± 7.22-5.35 ± 7.17-7.54 ± 7.94-6.64 ± 6.43-9.27 ± 6.58
SecondaryTime to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period

The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. The MID for ISS7 was a change of 5.0 points. Time to first ISS7 MID response (ISS7 \>=5) was defined as time to reduction from baseline of 5 points or more. Kaplan-Meier estimate is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.

Time frame:
Baseline (Day 1) up to Week 24
Reported as:
Median · weeks
Time to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period
weeksStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Time to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period4.0 (2.0 to 8.0)3.0 (2.0 to 5.0)4.0 (2.0 to 7.0)3.0 (2.0 to 4.0)5.0 (3.0 to 7.0)3.5 (3.0 to 5.0)
SecondaryChange From Baseline in Angioedema Activity Score Over 7 Days (AAS7) at Weeks 12 and 24

The AAS is a diary in which participants document on a daily basis the presence or absence of angioedema during the past 24 hours. If angioedema is present, participants answer 5 additional questions about the time of the day the swelling episode occurred and the severity and impact on daily functioning and appearance this swelling episode has had. Each AAS item is scored between 0 (minimum) and 3 (maximum). The daily AASs range from 0 (no episode) to 15 (severe) points. The AAS7 score is the sum of daily AAS scores reported by a participant at the same time of each day over 7 days, with a range of 0 (no angioedema episodes) to 105 (highest angioedema severity). Higher scores indicate greater angioedema activity. Mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day 1) and Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Angioedema Activity Score Over 7 Days (AAS7) at Weeks 12 and 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 12-23.46 ± 21.76-19.14 ± 18.89-16.74 ± 21.74-19.41 ± 34.44-32.14 ± 32.15-34.33 ± 36.19
Week 24-23.56 ± 23.04-18.76 ± 22.85-15.83 ± 25.73-13.95 ± 37.22-31.00 ± 36.38-36.28 ± 27.61
SecondaryPercentage of Well-controlled Participants (Urticaria Control Test >=12) at Weeks 12 and 24

The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; QoL impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. An UCT score of \>=12 (out of maximum 16) indicated a well-controlled urticaria disease status.

Time frame:
Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Well-controlled Participants (Urticaria Control Test >=12) at Weeks 12 and 24
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 1227.944.318.551.922.137.8
Week 2430.948.620.444.439.050.0
SecondaryChange From Baseline in Health-related Quality-of-life (HRQoL) as Measured by Dermatology Life Quality Index (DLQI) in Participants >=16 Years Old at Weeks 12 and 24

The DLQI is an assessment assessing the impact of skin disease on participants' HRQoL over the previous week and contains 10 questions related to symptoms, leisure activities, work/school or holiday time, personal relationships including intimate, the side effects of treatment, and emotional reactions to having a skin disease. The questions (except question 7) were scored on a 4-point Likert scale: 0 (not at all), 1 (a little), 2 (a lot), 3 (very much). Question 7 about work/studying asked whether work/study had been prevented and then (if "No") to what degree the skin condition has been a problem at work/study; the item was again rated on a 3-point Likert scale: 0 (not at all) to 3 (a lot). Total DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

Time frame:
Baseline (Day 1) and Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Health-related Quality-of-life (HRQoL) as Measured by Dermatology Life Quality Index (DLQI) in Participants >=16 Years Old at Weeks 12 and 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 12-7.55 ± 7.47-8.55 ± 6.27-4.53 ± 6.28-6.77 ± 6.92-5.01 ± 6.25-6.61 ± 7.04
Week 24-7.56 ± 8.13-9.50 ± 5.92-4.96 ± 6.87-6.91 ± 7.51-6.81 ± 6.54-8.09 ± 7.66
SecondaryChange From Baseline in Health-related Quality-of-life as Measured by Children's Dermatology Life Quality Index (CDLQI) in Participants >=6 to <16 Years Old at Weeks 12 and 24

The CDLQI is a validated questionnaire designed to measure the impact of skin disease on children's HRQoL. Participants provide responses to 10 questions (symptoms feelings associated with disease, the impact of the disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease). The instrument has a recall period of 7 days. 9 of the 10 questions are scored on a 4-point Likert scale ranging from 0 (not at all/question unanswered) to 3 (very much). Question 7 has an additional possible response (prevented school) which is assigned a score of 3 (0 \[not at all\] to 3 \[definitely\]). The total CDLQI score is the sum of the score of each question ranging 0 (no impact) to 30 (severe impact). The higher the score, the greater the impact is on the child's HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

Time frame:
Baseline (Day 1) and Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Health-related Quality-of-life as Measured by Children's Dermatology Life Quality Index (CDLQI) in Participants >=6 to <16 Years Old at Weeks 12 and 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 12-5.00 ± NA-8.00 ± 5.66—-7 ± NA-4.60 ± 10.04-9.00 ± 2.83
Week 24—-12.50 ± 12.02—-7 ± NA-5.60 ± 7.83-4.50 ± 7.78
SecondaryPatient Global Impression of Change (PGIC) of Chronic Spontaneous Urticaria at Weeks 12 and 24

The PGIC is a 1-item questionnaire that asks the participant to provide the overall self-assessment of change in their CSU on a 7-point scale compared to just before participant started taking the study intervention. Response choices are: 0 (very much better), 1 (moderately better), 2 (a little better), 3 (no change), 4 (a little worse), 5 (moderately worse), 6 (very much worse). Higher score indicate worsening.

Time frame:
Weeks 12 and 24
Reported as:
Mean · score on a scale
Patient Global Impression of Change (PGIC) of Chronic Spontaneous Urticaria at Weeks 12 and 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 121.68 ± 1.431.10 ± 1.242.06 ± 1.291.62 ± 1.461.59 ± 1.231.27 ± 1.44
Week 241.70 ± 1.501.04 ± 1.511.90 ± 1.641.44 ± 1.551.18 ± 1.361.01 ± 1.48
SecondaryChange From Baseline in Patient Global Impression of Severity (PGIS) of Chronic Spontaneous Urticaria at Weeks 12 and 24

The PGIS is a 1-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Response choices are: 1 (none), 2 (mild), 3 (moderate), 4 (severe). Higher score indicate more severity. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.

Time frame:
Baseline (Day 1) and Weeks 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Impression of Severity (PGIS) of Chronic Spontaneous Urticaria at Weeks 12 and 24
score on a scaleStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Week 12-0.89 ± 0.98-1.23 ± 0.93-0.46 ± 0.93-1.15 ± 1.04-0.82 ± 0.98-0.95 ± 0.97
Week 24-0.97 ± 1.18-1.44 ± 0.92-0.54 ± 1.16-0.96 ± 1.05-1.03 ± 1.09-1.33 ± 1.05
SecondaryTime to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period

Participants receiving OCS as rescue medications for CSU were recorded by the Investigator in e-case report form (eCRF) during the 24-week treatment period. Kaplan-Meier estimate for time to first OCS use is presented.

Time frame:
Baseline (Day 1) up to Week 24
Reported as:
Median · weeks
Time to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period
weeksStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Time to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period0.110 (0.048 to 0.200)0.087 (0.035 to 0.168)0.158 (0.074 to 0.271)0.116 (0.047 to 0.220)0.067 (0.025 to 0.138)0.014 (0.001 to 0.068)
SecondaryPercentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period

Percentage of participants receiving OCS as rescue medications for CSU were recorded by the Investigator in eCRF during the 24-week treatment period.

Time frame:
Baseline (Day 1) up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period
percentage of participantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Percentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period10.38.614.811.16.51.4
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

Time frame:
From first dose of study intervention (Day 1) up to end of follow-up, approximately 36 weeks each for Study A, B and C
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
TEAEs403829334140
TESAEs522315
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab

Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab
ParticipantsStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab1921001

Adverse events

Collected over From first dose of study intervention (Day 1) up to end of follow-up, approximately 36 weeks each for Study A, B and C. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study A: Placebo1/68 (1.5%)5/68 (7.4%)19/68 (27.9%)
Study A: Dupilumab0/70 (0%)2/70 (2.9%)12/70 (17.1%)
Study B: Placebo0/54 (0%)2/54 (3.7%)15/54 (27.8%)
Study B: Dupilumab0/54 (0%)3/54 (5.6%)17/54 (31.5%)
Study C: Placebo0/77 (0%)1/77 (1.3%)15/77 (19.5%)
Study C: Dupilumab0/74 (0%)5/74 (6.8%)20/74 (27%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Intestinal ObstructionGastrointestinal disorders0/680/700/541/540/770/74
Chronic Spontaneous UrticariaSkin and subcutaneous tissue disorders0/680/700/541/540/770/74
Idiopathic AngioedemaSkin and subcutaneous tissue disorders0/680/700/541/540/770/74
OsteoarthritisMusculoskeletal and connective tissue disorders0/680/701/540/540/770/74
Pain In ExtremityMusculoskeletal and connective tissue disorders0/680/701/540/540/770/74
Covid-19 PneumoniaInfections and infestations1/680/700/540/540/770/74
Completed SuicidePsychiatric disorders1/680/700/540/540/770/74
DyspnoeaRespiratory, thoracic and mediastinal disorders1/680/700/540/540/770/74
Abdominal Pain UpperGastrointestinal disorders1/680/700/540/540/770/74
NauseaGastrointestinal disorders1/680/700/540/540/770/74
Most frequent other events
Most frequent other events
EventStudy A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: Dupilumab
Chronic Spontaneous UrticariaSkin and subcutaneous tissue disorders6/683/703/546/543/772/74
Covid-19Infections and infestations2/681/704/545/544/776/74
NasopharyngitisInfections and infestations3/681/704/541/546/774/74
Accidental OverdoseInjury, poisoning and procedural complications0/681/702/543/542/775/74
AngioedemaSkin and subcutaneous tissue disorders4/681/700/542/541/773/74
Injection Site ErythemaGeneral disorders4/683/703/540/540/774/74
Injection Site ReactionGeneral disorders2/684/701/541/541/773/74
HypertensionVascular disorders0/680/701/543/540/770/74

Baseline characteristics

Analysis was performed on randomized population.

Age, Continuous
Age, Continuous(years)Study A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: DupilumabTotal
Mean41.9 ± 14.840.7 ± 16.246.8 ± 16.348.6 ± 15.644.0 ± 16.745.6 ± 17.144.4 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)Study A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: DupilumabTotal
Female504141375947275
Male182913171827122
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: DupilumabTotal
American Indian or Alaska Native0100012
Asian16191162933114
Native Hawaiian or Other Pacific Islander0001001
Black or African American21232010
White484741433832249
More than one race1100215
Unknown or Not Reported11016716
Weekly Itch-Severity (ISS7) Score
Weekly Itch-Severity (ISS7) Score(score on a scale)Study A: PlaceboStudy A: DupilumabStudy B: PlaceboStudy B: DupilumabStudy C: PlaceboStudy C: DupilumabTotal
Mean15.7 ± 4.116.1 ± 4.016.2 ± 3.815.9 ± 4.015.0 ± 3.915.3 ± 3.615.7 ± 3.9
08

Study locations

98 sites
  • California Allergy and Asthma Medical Group, Inc. Site Number : 8400019
    Los Angeles, California 90025, United States
  • Sarasota Clinical Research Site Number : 8400017
    Sarasota, Florida 34239, United States
  • Lenus Research & Medical Group Site Number : 8400001
    Sweetwater, Florida 33172, United States
  • University of South Florida Site Number : 8400006
    Tampa, Florida 33613, United States
  • Aeroallergy Research Laboratories of Savannah, INC Site Number : 8400018
    Savannah, Georgia 31406, United States
  • Allergy & Asthma Specialists, PSC Site Number : 8400020
    Owensboro, Kentucky 42301, United States
  • Johns Hopkins University (Asthma and Allergy Center) Site Number : 8400016
    Baltimore, Maryland 21224, United States
  • The Clinical Research Center, LLC Site Number : 8400009
    St Louis, Missouri 63141, United States
  • UR Dermatology at College Town Site Number : 8400008
    Rochester, New York 14642, United States
  • Immunocarolina LLC Site Number : 8400010
    Charlotte, North Carolina 28277, United States
  • Bernstein Clinical Research Center Site Number : 8400014
    Cincinnati, Ohio 45236, United States
  • Vital Prospects Clinical Research Institute, P.C. Site Number : 8400015
    Tulsa, Oklahoma 74136, United States
  • Allergy and Clinical Immunology Associates Site Number : 8400024
    Pittsburgh, Pennsylvania 15241, United States
  • National Allergy and ENT Site Number : 8400011
    Charleston, South Carolina 29420, United States
  • Pharmaceutical Research & Consulting, Inc. Site Number : 8400003
    Dallas, Texas 75231, United States
  • STAAMP Research, LLC Site Number : 8400007
    San Antonio, Texas 78229, United States
  • Investigational Site Number : 0320008
    CABA, Buenos Aires C1023AAB, Argentina
  • Investigational Site Number : 0320004
    CABA, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province S2000BRH, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe Province S2000JKR, Argentina
  • Investigational Site Number : 0320003
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number : 1240009
    Calgary, Alberta T2J 7E1, Canada
  • Investigational Site Number : 1240010
    Edmonton, Alberta T6G 1C3, Canada
  • Investigational Site Number : 1240014
    Hamilton, Ontario L8L 3C3, Canada
  • Investigational Site Number : 1240013
    Markham, Ontario L3P 1X3, Canada
  • Investigational Site Number : 1240003
    Niagara Falls, Ontario L2H 1H5, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M3B 3S6, Canada
  • Investigational Site Number : 1240002
    Toronto, Ontario M5G 1E2, Canada
  • Investigational Site Number : 1240007
    Windsor, Ontario N8X 2G1, Canada
  • Investigational Site Number : 1240016
    Sherbrooke, Quebec J1G 1X9, Canada
  • Investigational Site Number : 1240006
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number : 1240004
    Québec, G1V 4W2, Canada
  • Investigational Site Number : 1240011
    Québec, G1W 4R4, Canada
  • Investigational Site Number : 1560010
    Beijing, 100045, China
  • Investigational Site Number : 1560004
    Beijing, 100050, China
  • Investigational Site Number : 1560001
    Chengdu, 610041, China
  • Investigational Site Number : 1560007
    Guangzhou, 510630, China
  • Investigational Site Number : 1560002
    Hangzhou, 310006, China
  • Investigational Site Number : 1560008
    Hangzhou, 310016, China
  • Investigational Site Number : 1560006
    Jinan, 250013, China
  • Investigational Site Number : 1560003
    Shanghai, 200040, China
  • Investigational Site Number : 1560005
    Wuxi, 214002, China
  • Investigational Site Number : 2500009
    Calais, 62107, France
  • Investigational Site Number : 2500002
    Lille, 59037, France
  • Investigational Site Number : 2500011
    Mont-de-Marsan, 40000, France
  • Investigational Site Number : 2500004
    Nantes, 44093, France
  • Investigational Site Number : 2500012
    Nice, 06000, France
  • Investigational Site Number : 2500003
    Nice, 06200, France
  • Investigational Site Number : 2500006
    Paris, 75970, France
  • Investigational Site Number : 2500005
    Pierre-Bénite, 69495, France
  • Investigational Site Number : 2760001
    Berlin, 10117, Germany
  • Investigational Site Number : 2760010
    Bramsche, 49565, Germany
  • Investigational Site Number : 2760006
    Dresden, 01307, Germany
  • Investigational Site Number : 2760007
    Kiel, 24148, Germany
  • Investigational Site Number : 2760008
    Tübingen, 72076, Germany
  • Investigational Site Number : 3480005
    Debrecen, 4031, Hungary
  • Investigational Site Number : 3480004
    Szeged, 6720, Hungary
  • Investigational Site Number : 3480003
    Szolnok, 5000, Hungary
  • Investigational Site Number : 3480002
    Szombathely, 9700, Hungary
  • Investigational Site Number : 3920005
    Hiroshima, Hiroshima 734-8551, Japan
  • Investigational Site Number : 3920009
    Sapporo, Hokkaido 060-0807, Japan
  • Investigational Site Number : 3920002
    Kobe, Hyōgo 650-0017, Japan
  • Investigational Site Number : 3920011
    Kagoshima, Kagoshima-ken 890-0063, Japan
  • Investigational Site Number : 3920013
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number : 3920008
    Yokohama, Kanagawa 236-0004, Japan
  • Investigational Site Number : 3920003
    Suita-shi, Osaka 565-0871, Japan
  • Investigational Site Number : 3920007
    Izumo-shi, Shimane 693-8501, Japan
  • Investigational Site Number : 3920006
    Itabashi-ku, Tokyo 173-8610, Japan
  • Investigational Site Number : 3920001
    Shinagawa-Ku, Tokyo 141-8625, Japan
  • Investigational Site Number : 3920010
    Tachikawa-shi, Tokyo 190-0023, Japan
  • Investigational Site Number : 3920004
    Nagoya, 454-8509, Japan
  • Investigational Site Number : 6430008
    Chelyabinsk, 454048, Russia
  • Investigational Site Number : 6430006
    Kazan', 420064, Russia
  • Investigational Site Number : 6430007
    Krasnodar, 350020, Russia
  • Investigational Site Number : 6430005
    Moscow, 115522, Russia
  • Investigational Site Number : 6430010
    Moscow, 115522, Russia
  • Investigational Site Number : 6430002
    Moscow, 123182, Russia
  • Investigational Site Number : 6430003
    Saint Petersburg, 193231, Russia
  • Investigational Site Number : 6430009
    Saratov, 410028, Russia
  • Investigational Site Number : 6430004
    Smolensk, 214006, Russia
  • Investigational Site Number : 6430001
    Stavropol, 355030, Russia
  • Investigational Site Number : 7240012
    Santiago de Compostela, A Coruña [La Coruña] 15702, Spain
  • Investigational Site Number : 7240003
    Barcelona, Barcelona [Barcelona] 08003, Spain
  • Investigational Site Number : 7240008
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number : 7240014
    L'Hospitalet de Llobregat, Barcelona [Barcelona] 08907, Spain
  • Investigational Site Number : 7240010
    Esplugues de Llobregat, Catalunya [Cataluña] 08950, Spain
  • Investigational Site Number : 7240005
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
  • Investigational Site Number : 7240007
    Madrid, Madrid, Comunidad de 28027, Spain
  • Investigational Site Number : 7240001
    Madrid, Madrid, Comunidad de 28040, Spain
  • Investigational Site Number : 7240006
    Madrid, Madrid, Comunidad de 28041, Spain
  • Investigational Site Number : 7240002
    Pamplona, Navarre 31008, Spain
  • Investigational Site Number : 7240013
    Burjassot - Valencia, Valenciana, Comunidad 46100, Spain
  • Investigational Site Number : 7240004
    Córdoba, 14004, Spain
  • Investigational Site Number : 7240011
    Villarreal de Huerva, 12540, Spain
  • Investigational Site Number : 8260002
    London, London, City of E1 1BB, United Kingdom
  • Investigational Site Number : 8260001
    Manchester, M23 9QZ,, United Kingdom
09

References and documents

Publications

  • Casale TB, Saini SS, Ben-Shoshan M, Gimenez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. JAMA Dermatol. 2026 Apr 1;162(4):350-358. doi: 10.1001/jamadermatol.2025.6023. PubMed 41706458 ↗
  • Gimenez-Arnau AM, Casale TB, Yosipovitch G, Ensina LF, Inomata N, Msihid J, Makhija M, Radin A, Cyr SL, Sugerman P, Thomas RB, Chuang CC. Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria. Dermatol Ther (Heidelb). 2026 Jan;16(1):549-562. doi: 10.1007/s13555-025-01605-w. Epub 2025 Dec 2. PubMed 41326897 ↗
  • Yosipovitch G, Kim BS, Koo JY, Chen Z, Wiggins S, Zahn J, Sugerman P, Haddad EB, Cyr SL. Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria. Dermatol Ther (Heidelb). 2026 Apr;16(4):1983-1995. doi: 10.1007/s13555-025-01596-8. Epub 2025 Nov 22. PubMed 41272364 ↗
  • Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Laws E, Maloney J, Bauer D, Radin A, Makhija M. Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels. Dermatol Ther (Heidelb). 2024 Sep;14(9):2427-2441. doi: 10.1007/s13555-024-01231-y. Epub 2024 Jul 27. PubMed 39066978 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Aug 2024, 55 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 55 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 27, 2019
StartActual
Dec 11, 2019
Primary completionActual
Aug 1, 2024
CompletionActual
Oct 25, 2024
Results first posted
Aug 20, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04180488
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Dec 11, 2019
Primary completion
Aug 1, 2024
Completion
Oct 25, 2024
Results posted
Aug 20, 2025
Last update
Aug 20, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion